Efinaconazole Emerges as Viable Onychomycosis Therapy

Efinaconazole Emerges as Viable Onychomycosis Therapy

Efinaconazole-CAS-164650-44-6Onychomycosis of the toenail as a result of either Trichophyton mentagrophytes or Trichophyton rubrum can be a painful and debilitating condition. Efinaconazole has emerged as a viable topical contender for treating this frustrating fungus, becoming an FDA approved topical therapy. Known as the brand name Jublia, which is marketed by Valeant Pharmaceuticals, this novel and newly approved remedy to combat onychomycosis is exciting. Prior to the approval of Jublia (Efinaconazole) the only topical –type treatment approved was ciclopirox nail lacquer, which unfortunately held dismal complete cure rates and led to a need for frequent nail debridement post treatment for many patients. Oral antifungal therapy, while often prescribed for onychomycosis, has shown to be a non-preferred option for a wide variety of patients due to concerns for side effects and difficulty adhering to treatment daily. As the most commonly diagnosed nail disease in the United States onychomycosis affects more than 35 million Americans. Additionally, onychomycosis is the number one condition both diagnosed and treated by podiatrists in the U.S. today.

As an effectual antifungal inhibitor of sterol 14α-demethylase, Efinaconazole demonstrated complete cure rates of 17.8% and 15.2% in phase 3 clinical trials. Efinaconazole 10% nail solution has proven in several comprehensive studies to be an effective monotherapy for both distal and lateral subungual onychomycosis. Efinaconazole, as Jublia, is prescribed to be applied one time daily for 48 weeks. The progression of toenail fungus can be hard to treat, and diligence with medication adherence is key for getting rid of this unsightly and unwanted condition. No serious effects from treatment with Efinaconazole were determined, with minor side effects reported including redness, itching and slight swelling. Untreated onychomycosis often leads to the spread of infection to other nails, as well as complications in overall health, particularly for patients who are immunocompromised or are diabetic.

LGM Pharma can assist clients as a supplier/distributor of the API Efinaconazole, CAS # 164650-44-6 for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service